292 related articles for article (PubMed ID: 30022586)
1. Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review.
Akizawa T; Okumura H; Alexandre AF; Fukushima A; Kiyabu G; Dorey J
Ther Apher Dial; 2018 Oct; 22(5):444-456. PubMed ID: 30022586
[TBL] [Abstract][Full Text] [Related]
2. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.
Spinowitz B; Pecoits-Filho R; Winkelmayer WC; Pergola PE; Rochette S; Thompson-Leduc P; Lefebvre P; Shafai G; Bozas A; Sanon M; Krasa HB
J Med Econ; 2019 Jun; 22(6):593-604. PubMed ID: 30813807
[No Abstract] [Full Text] [Related]
3. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
5. A retrospective database analysis of erythropoiesis-stimulating agent treatment patterns and associated healthcare resource use in patients with non-dialysis-dependent chronic kidney disease-related anaemia in Japan.
Mishina S; Waratani M; Onozawa S; Okumura H; Ito Y; Yasuda Y
Nephrology (Carlton); 2023 Aug; 28(8):446-455. PubMed ID: 37161826
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
7. [The therapeutic management and economic burden of patients with chronic kidney disease non-dialysis-dependent with anemia and ESA treated: findings from a real-world study in Italy].
Ravera M; Mené P; Degli Esposti L; Sangiorgi D; Di Rienzo P
G Ital Nefrol; 2023 Feb; 40(1):. PubMed ID: 36883922
[No Abstract] [Full Text] [Related]
8. Characteristics of Japanese patients with non-dialysis-dependent chronic kidney disease initiating treatment for anemia: a retrospective real-world database study.
Kokado Y; Ishii M; Ueta K; Yamamoto H; Kumamaru H; Isshiki M; Demiya S; Miyata H
Curr Med Res Opin; 2022 Dec; 38(12):2175-2182. PubMed ID: 36111421
[TBL] [Abstract][Full Text] [Related]
9. [ANEMIA IN CHRONIC KIDNEY DISEASE].
Bukmir L; Fišić M; Diminić-Lisica I; Ljubotina A
Acta Med Croatica; 2016 Dec; 70(4-5):217-24. PubMed ID: 29087100
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V; Graziano G; McGee R; Nicolucci A; Tognoni G; Strippoli GF
Ann Intern Med; 2010 Jul; 153(1):23-33. PubMed ID: 20439566
[TBL] [Abstract][Full Text] [Related]
11. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia.
Eriksson D; Goldsmith D; Teitsson S; Jackson J; van Nooten F
BMC Nephrol; 2016 Jul; 17(1):97. PubMed ID: 27460779
[TBL] [Abstract][Full Text] [Related]
12. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
[TBL] [Abstract][Full Text] [Related]
13. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.
Tsuruya K; Yoshida H; Suehiro T; Fujisaki K; Masutani K; Kitazono T
Ren Fail; 2016; 38(3):390-6. PubMed ID: 26822074
[TBL] [Abstract][Full Text] [Related]
14. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).
Sofue T; Nakagawa N; Kanda E; Nagasu H; Matsushita K; Nangaku M; Maruyama S; Wada T; Terada Y; Yamagata K; Narita I; Yanagita M; Sugiyama H; Shigematsu T; Ito T; Tamura K; Isaka Y; Okada H; Tsuruya K; Yokoyama H; Nakashima N; Kataoka H; Ohe K; Okada M; Kashihara N
PLoS One; 2020; 15(7):e0236132. PubMed ID: 32687544
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Collister D; Komenda P; Hiebert B; Gunasekara R; Xu Y; Eng F; Lerner B; Macdonald K; Rigatto C; Tangri N
Ann Intern Med; 2016 Apr; 164(7):472-8. PubMed ID: 26881842
[TBL] [Abstract][Full Text] [Related]
17. Treatment and costs associated with anemic chronic kidney disease patients.
Rasu RS; Crawford T; Manley H; Balkrishnan R
Curr Med Res Opin; 2008 Jan; 24(1):129-37. PubMed ID: 18034919
[TBL] [Abstract][Full Text] [Related]
18. The Cost and Quality of Life of Malaysian Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease and Anemia.
Azmi S; Goh A; Muhammad NA; Tohid H; Rashid MRA
Value Health Reg Issues; 2018 May; 15():42-49. PubMed ID: 29474177
[TBL] [Abstract][Full Text] [Related]
19. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia.
Arantes LH; Crawford J; Gascon P; Latymer M; Launay-Vacher V; Rolland C; Scotte F; Wish J
Crit Rev Oncol Hematol; 2018 Sep; 129():79-90. PubMed ID: 30097240
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of anemia in predialysis chronic kidney disease patients.
Shaheen FA; Souqiyyeh MZ; Al-Attar BA; Karkar A; Al Jazairi AM; Badawi LS; Ballut OM; Hakami AH; Naguib M; Al-Homrany MA; Barhamein MY; Ahmed AM; Khardaji MM; Said SA;
Saudi J Kidney Dis Transpl; 2011 May; 22(3):456-63. PubMed ID: 21566300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
